You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
錦欣生殖(01951.HK)逆市續漲9% 入股兩間民營醫院權益獲瑞信及花旗看好
錦欣生殖(01951.HK)入股雲南兩間民營醫院權益後,獲瑞信及花旗維持正面評級分別看21.2元及25元,該股三連升,今天逆市升破50天及20天線(19.2元及19.4元),最高見20.9元,現造20.05元,續升9%,成交續增至3,795萬股,涉資7.648億元。

錦欣生殖公佈,附屬四川錦欣生殖上週五(18日)與康芝藥業(300086.SZ)旗下廣東元寧製藥訂立股權轉讓協議,四川錦欣生殖將以3,774萬元人民幣收購分別持有雲南九洲醫院及昆明和萬家婦產醫院醫51%股權的康芝醫院一成權益;而公司持有15%合夥權益的濱海遠賢則會購入康芝醫院餘下九成股權,以及收購九洲醫院及和萬家醫院餘下49%股權。交易完成後,公司將間接享有該兩間醫院約19.33%經濟利益。

瑞信指,錦欣生殖分別入股雲南昆明民營營利性二級綜合醫院「九洲醫院」和三級婦產專科醫院「和萬家醫院」,將間接享有該等醫院約19.33%的經濟利益。該行指,上述交易估值合理,其中一間收購醫院更是雲南第二大試管嬰兒醫院,兩間醫院潛在產能可能增加兩倍以上。該行慮到到今次交易和未來潛在併購積極影響,維持錦欣生殖「跑贏大市」評級,目標價由18.5元調高至21.2元。此外,花旗也指,九洲醫院及和萬家醫院合共估值達7.4億元人民幣,上述收購有助錦欣生殖擴大西南地區市場份額,加上公司聘請中國知名試管嬰兒醫生Ma Yanping,這是一個重大利好,故重申其「買入」評級看25元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account